Lartruvo
Lartruvo (olaratumab) is an injectable medication that's given together with doxorubicin (Adriamycin) for the treatment of soft tissue sarcoma (STS) in adults who can't get surgery or radiotherapy. This medication was taken off the market and is no longer available in the U.S.
What is Lartruvo (olaratumab)?
What is Lartruvo (olaratumab) used for?
- Soft tissue sarcoma (STS)
Drug facts
Common questions about Lartruvo (olaratumab)
Lartruvo (olaratumab) is an anticancer medication used to treat soft tissue sarcoma (STS) for people who can't get surgery or radiotherapy. This medication is given as an infusion into the vein and in combination with doxorubicin (Adriamycin) treatment. Lartruvo (olaratumab) works by attaching to a protein on the surface of cells that's responsible for growth and movement. Since this protein is also found on cancer cells (including those of STS), blocking the protein can help slow or stop the growth of the cancer. Lartruvo (olaratumab) was approved by the FDA in 2016 under their Accelerated Approval program based on early studies showing potential benefits of the medication to people with this rare cancer.
No, Lartruvo (olaratumab) has been withdrawn from the market and is no longer available.
Lartruvo (olaratumab) was discontinued by the manufacturer (Eli Lilly and Co.), because there wasn't enough clinical evidence that the medication could improve survival for people with STS. Because of this, the FDA decided to withdraw Lartruvo (olaratumab) from the market. Speak with your provider about other treatment options for your particular STS.
How to save using GoodRx
